Kusajili – Clinical trials directory

Result of your search per sponsor: Timothy Illidge, Prof

Woman and Man Max 99 years
Timothy Illidge, Prof Update Il y a 4 ans

Phase II Study of Fractionated 90Y Ibritumomab Tiuxetan (Zevalin) Radioimmunotherapy as an Initial Therapy of Follicular Lymphoma 90Y Ibritumomab tiuxetan (zevalin) has demonstrated consistently high response rates in patients who have received previous treatment for lymphoma. More than two-thirds of the patients who...

Country France, United Kingdom
organs None
Specialty None

unknown

More information